Pathophysiology of inhibitors to factor VIII in patients with haemophilia A

The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti‐idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors. We briefly conclude on the avenues that remain to be explored in order to establish efficient therapeutic approaches aimed at eliminating FVIII inhibitors in patients with haemophilia A.

[1]  G. E. Gilbert,et al.  Slowed Release of Thrombin-cleaved Factor VIII from von Willebrand Factor by a Monoclonal and a Human Antibody Is a Novel Mechanism for Factor VIII Inhibition* , 1996, The Journal of Biological Chemistry.

[2]  S. Kaveri,et al.  Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. , 2000, Blood.

[3]  C. Fulcher.  Immunochemistry of factor VIII:C inhibitor antibodies. , 1991, The American journal of medicine.

[4]  M. Shima,et al.  A Factor VIII Neutralizing Monoclonal Antibody and a Human Inhibitor Alloantibody Recognizing Epitopes in the C2 Domain Inhibit Factor VIII Binding to von Willebrand Factor and to Phosphatidylserine , 1993, Thrombosis and Haemostasis.

[5]  T. VandenDriessche,et al.  Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D. Green,et al.  A More Uniform Measurement of Factor VIII Inhibitors , 1975, Thrombosis and Haemostasis.

[7]  W. Ouwehand,et al.  Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. , 2000, Blood.

[8]  B. Dahlbäck,et al.  Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients. , 1990, Blood.

[9]  M. Kazatchkine,et al.  Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. , 1988, Clinical and experimental immunology.

[10]  M. Kazatchkine,et al.  Circulating immune complexes containing anti-VIII antibodies in multi-transfused patients with haemophilia A. , 1980, Clinical and Experimental Immunology.

[11]  J. Vermylen,et al.  A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. , 2000, Blood.

[12]  J. E. Curtis,et al.  Inhibition of human factor VIIIa by anti-A2 subunit antibodies. , 1994, The Journal of clinical investigation.

[13]  J. Vermylen,et al.  Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. , 1996, The Journal of clinical investigation.

[14]  C. Fulcher,et al.  Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time. , 1988, Blood.

[15]  M. van den Berg,et al.  The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.

[16]  L. Hoyer,et al.  Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. , 1989, The Journal of clinical investigation.

[17]  N. Key,et al.  Sensitization of CD4+ T Cells to Coagulation Factor VIII: Response in Congenital and Acquired Hemophilia Patients and in Healthy Subjects , 2000, Thrombosis and Haemostasis.

[18]  J. Voorberg,et al.  Multiple VH genes are used to assemble human antibodies directed toward the A 3C 1 domains of factor VIII , 2001 .

[19]  R. Biggs,et al.  The Mode of Action of Antibodies which Destroy Factor VIII , 1972, British journal of haematology.

[20]  Richard E. Dixon.  Historical perspective: The landmark conference in 1980 , 1991 .

[21]  D. Dimichele,et al.  Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. , 2000, Haematologica.

[22]  M. Kazatchkine,et al.  Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). , 1992, Blood.

[23]  S. Miller,et al.  Evolution of the T‐Cell Repertoire during the Course of Experimental Immune‐Mediated Demyelinating Diseases , 1995, Immunological reviews.

[24]  M. Hultin.  Acquired inhibitors in malignant and nonmalignant disease states. , 1991, The American journal of medicine.

[25]  R. Houghten,et al.  Localization of the binding site for a factor VIII activity neutralizing antibody to amino acid residues Asp1663-Ser1669. , 1988, The Journal of biological chemistry.

[26]  M. Shima,et al.  Some human inhibitor antibodies interfere with factor VIII binding to factor IX. , 1998, Blood.

[27]  S. Shapiro.  The immunologic character of acquired inhibitors of antihemophilic globulin (factor 8) and the kinetics of their interaction with factor 8. , 1967, The Journal of clinical investigation.

[28]  S. Kaveri,et al.  Catalytic activity of antibodies against factor VIII in patients with hemophilia A , 1999, Nature Medicine.

[29]  J. Ware,et al.  Identification of a F.VIII epitope recognized by a human hemophilic inhibitor. , 1989, Blood.

[30]  S. Kaveri,et al.  Idiotypic regulation of anti-factor VIII antibodies. , 2000, Haematologica.

[31]  C. Fulcher,et al.  Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Oldenburg,et al.  Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation , 1995, Thrombosis and Haemostasis.

[33]  A. Sharpe,et al.  Prevention and treatment of factor VIII inhibitors in murine hemophilia AJ. Qian, M. Collins, A.H. Sharpe, et al. Blood 95:1324–1329, 2000 , 2000 .

[34]  M. Shima,et al.  A role for the C2 domain of factor VIII in binding to von Willebrand factor. , 1994, The Journal of biological chemistry.

[35]  S. Kaveri,et al.  The prevalence of proteolytic antibodies against factor VIII in hemophilia A. , 2002, The New England journal of medicine.

[36]  G. E. Gilbert,et al.  Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. , 1995, Blood.

[37]  G. Mariani,et al.  Immune Tolerance in Hemophilia-Principal Results from the International Registry , 1994, Thrombosis and Haemostasis.

[38]  J. Voorberg,et al.  Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain. , 2000, Blood.

[39]  J. Roberts,et al.  Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[40]  L. Timmons,et al.  A Soluble Recombinant Factor VIII Fragment Containing the A2 Domain Binds to Some Human Anti-Factor VIII Antibodies that Are not Detected by Immunoblotting , 1992, Thrombosis and Haemostasis.

[41]  L. Burkly,et al.  Role of CD154 in the secondary immune response: the reduction of pre‐existing splenic germinal centers and anti‐factor VIII inhibitor titer , 2000, European journal of immunology.

[42]  M. Kazatchkine,et al.  Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Houghten,et al.  Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. , 1988, The Journal of clinical investigation.

[44]  M F Hoylaerts,et al.  Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. , 1998, Blood.

[45]  K. Fujikawa,et al.  Structure of the C2 domain of human factor VIII at 1.5 Å resolution , 1999, Nature.

[46]  J. Arnout,et al.  Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. , 1993, Blood.

[47]  C. Kessler,et al.  An introduction to factor VIII inhibitors: the detection and quantitation. , 1991, The American journal of medicine.

[48]  M. Kazatchkine,et al.  ANTI-IDIOTYPIC SUPPRESSION OF AUTOANTIBODIES TO FACTOR VIII (ANTIHAEMOPHILIC FACTOR) BY HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN , 1984, The Lancet.

[49]  D. Scandella.  Human Anti‐Factor VIII Antibodies: Epitope Localization and Inhibitory Function , 1996, Vox sanguinis.

[50]  E. Sercarz,et al.  Determinant spreading and the dynamics of the autoimmune T-cell repertoire. , 1993, Immunology today.

[51]  M. Kazatchkine,et al.  Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[52]  H. Kazazian,et al.  Inhibitor Antibody Development and T Cell Response to Human Factor VIII in Murine Hemophilia A , 1999, Thrombosis and Haemostasis.

[53]  J. Saint-Remy,et al.  Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. , 1994, The Journal of clinical investigation.

[54]  D. Scandella,et al.  Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. , 2001, Blood.